$NLTX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Neoleukin Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Neoleukin Therapeutics, Inc.. Get notifications about new insider transactions in Neoleukin Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 09 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 11.00 | 600 | 6,600 | 1,353,739 | 1.4 M to 1.4 M (-0.04 %) |
| May 13 2021 | NLTX | Neoleukin Therapeu ... | Williams Lewis T | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
| May 13 2021 | NLTX | Neoleukin Therapeu ... | SIMPSON TODD E | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
| May 13 2021 | NLTX | Neoleukin Therapeu ... | Noonberg Sarah B. | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
| May 13 2021 | NLTX | Neoleukin Therapeu ... | Lavelle Erin M. | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
| May 13 2021 | NLTX | Neoleukin Therapeu ... | Babler Martin | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
| May 13 2021 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 11.40 | 25,000 | 285,000 | 25,000 | |
| May 12 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 11.09 | 1,200 | 13,308 | 1,354,762 | 1.4 M to 1.4 M (-0.09 %) |
| May 06 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 11.30 | 1,200 | 13,560 | 1,355,962 | 1.4 M to 1.4 M (-0.09 %) |
| Apr 30 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 12.58 | 2,400 | 30,192 | 1,357,162 | 1.4 M to 1.4 M (-0.18 %) |
| Apr 27 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 13.00 | 600 | 7,800 | 1,359,562 | 1.4 M to 1.4 M (-0.04 %) |
| Apr 22 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 11.98 | 1,800 | 21,564 | 1,360,162 | 1.4 M to 1.4 M (-0.13 %) |
| Apr 16 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 12.22 | 1,800 | 21,996 | 1,361,962 | 1.4 M to 1.4 M (-0.13 %) |
| Apr 08 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 12.02 | 1,800 | 21,636 | 1,363,762 | 1.4 M to 1.4 M (-0.13 %) |
| Apr 06 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 13.00 | 600 | 7,800 | 1,365,562 | 1.4 M to 1.4 M (-0.04 %) |
| Apr 02 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 11.96 | 1,800 | 21,528 | 1,366,162 | 1.4 M to 1.4 M (-0.13 %) |
| Mar 24 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 11.95 | 1,800 | 21,516 | 1,367,962 | 1.4 M to 1.4 M (-0.13 %) |
| Mar 24 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 12.00 | 600 | 7,200 | 1,369,762 | 1.4 M to 1.4 M (-0.04 %) |
| Mar 18 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 11.36 | 1,200 | 13,632 | 1,370,362 | 1.4 M to 1.4 M (-0.09 %) |
| Mar 18 2021 | NLTX | Neoleukin Therapeu ... | Ho Robert | Chief Financial Off ... | Option Exercise | M | 0.00 | 25,000 | 0 | 50,000 | |
| Mar 18 2021 | NLTX | Neoleukin Therapeu ... | Ho Robert | Chief Financial Off ... | Sell | S | 11.01 | 6,497 | 71,556 | 21,503 | 28 K to 21.5 K (-23.20 %) |
| Mar 18 2021 | NLTX | Neoleukin Therapeu ... | Ho Robert | Chief Financial Off ... | Buy | M | 0.00 | 25,000 | 0 | 28,000 | 3 K to 28 K (+833.33 %) |
| Mar 04 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 11.87 | 1,800 | 21,360 | 1,373,362 | 1.4 M to 1.4 M (-0.13 %) |
| Feb 25 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 13.00 | 600 | 7,800 | 1,375,162 | 1.4 M to 1.4 M (-0.04 %) |
| Feb 25 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 12.14 | 1,800 | 21,852 | 1,375,762 | 1.4 M to 1.4 M (-0.13 %) |
| Feb 09 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 14.00 | 600 | 8,400 | 1,382,962 | 1.4 M to 1.4 M (-0.04 %) |
| Feb 09 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 14.00 | 600 | 8,400 | 1,382,962 | 1.4 M to 1.4 M (-0.04 %) |
| Feb 05 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 13.23 | 2,400 | 31,752 | 1,383,562 | 1.4 M to 1.4 M (-0.17 %) |
| Feb 05 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Sell | S | 13.23 | 2,400 | 31,752 | 1,383,562 | 1.4 M to 1.4 M (-0.17 %) |
| Feb 02 2021 | NLTX | Neoleukin Therapeu ... | Walkey Carl | Senior Vice Preside ... | Option Exercise | A | 12.60 | 45,000 | 567,000 | 45,000 | |
| Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 518,555 | 0 | 10,283,888 | |
| Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | P | 0.00 | 38,974 | 0 | 1,199,122 | |
| Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 15.25 | 394,360 | 6,013,990 | 3,501,691 | 3.1 M to 3.5 M (+12.69 %) |
| Dec 23 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 15.25 | 29,640 | 452,010 | 320,049 | 290.4 K to 320 K (+10.21 %) |
| Oct 20 2020 | NLTX | Neoleukin Therapeu ... | Vance Holly | General Counsel | Option Exercise | A | 12.30 | 220,000 | 2,706,000 | 220,000 | |
| Sep 10 2020 | NLTX | Neoleukin Therapeu ... | Babler Martin | Director | Option Exercise | A | 12.25 | 50,000 | 612,500 | 50,000 | |
| Aug 12 2020 | NLTX | Neoleukin Therapeu ... | Ho Robert | Chief Financial Off ... | Option Exercise | A | 12.00 | 90,000 | 1,080,000 | 90,000 | |
| Aug 12 2020 | NLTX | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | President and CEO | Option Exercise | A | 12.00 | 420,000 | 5,040,000 | 420,000 | |
| May 07 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 12.84 | 25,000 | 321,000 | 25,000 | |
| May 07 2020 | NLTX | Neoleukin Therapeu ... | Williams Lewis T | Director | Option Exercise | A | 12.84 | 25,000 | 321,000 | 25,000 | |
| May 07 2020 | NLTX | Neoleukin Therapeu ... | SIMPSON TODD E | Director | Option Exercise | A | 12.84 | 25,000 | 321,000 | 25,000 | |
| May 07 2020 | NLTX | Neoleukin Therapeu ... | Noonberg Sarah B. | Director | Option Exercise | A | 12.84 | 25,000 | 321,000 | 25,000 | |
| May 07 2020 | NLTX | Neoleukin Therapeu ... | Nolan Sean P. | Director | Option Exercise | A | 12.84 | 25,000 | 321,000 | 25,000 | |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Sell | S | 11.82 | 100 | 1,182 | 4,041,211 | 4 M to 4 M (0.00 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Sell | S | 11.30 | 9,734 | 110,032 | 4,041,311 | 4.1 M to 4 M (-0.24 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 11.85 | 1,000 | 11,851 | 4,051,045 | 4.1 M to 4.1 M (+0.02 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 11.36 | 38,300 | 435,107 | 4,050,045 | 4 M to 4.1 M (+0.95 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Sell | S | 11.87 | 200 | 2,373 | 4,011,745 | 4 M to 4 M (0.00 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Sell | S | 11.06 | 9,634 | 106,567 | 4,011,945 | 4 M to 4 M (-0.24 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 11.65 | 9,000 | 104,865 | 4,021,579 | 4 M to 4 M (+0.22 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 10.95 | 33,500 | 366,765 | 4,012,579 | 4 M to 4 M (+0.84 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 10.71 | 7,500 | 80,309 | 3,979,079 | 4 M to 4 M (+0.19 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 10.18 | 22,500 | 229,079 | 3,971,579 | 3.9 M to 4 M (+0.57 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 10.27 | 2,700 | 27,741 | 3,949,079 | 3.9 M to 3.9 M (+0.07 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 9.91 | 29,800 | 295,169 | 3,946,379 | 3.9 M to 3.9 M (+0.76 %) |
| Apr 06 2020 | NLTX | Neoleukin Therapeu ... | Redmile Group, LLC | 10% Owner | Buy | P | 9.21 | 50,000 | 460,395 | 3,916,579 | 3.9 M to 3.9 M (+1.29 %) |
| Mar 16 2020 | NLTX | Neoleukin Therapeu ... | Ho Robert | Chief Financial Off ... | Option Exercise | A | 6.44 | 200,000 | 1,288,000 | 200,000 | |
| Mar 16 2020 | NLTX | Neoleukin Therapeu ... | Ho Robert | Chief Financial Off ... | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | President and CEO | Buy | P | 8.40 | 119,047 | 999,995 | 2,198,686 | 2.1 M to 2.2 M (+5.72 %) |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | President and CEO | Buy | C | 0.00 | 1,261,600 | 0 | 2,079,639 | 818 K to 2.1 M (+154.22 %) |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | President and CEO | Sell | C | 0.00 | 12,616 | 0 | 0 | 12.6 K to 0 (-100.00 %) |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 9,765,333 | 0 | 9,765,333 | |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 1,160,148 | 0 | 1,161,048 | |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Sell | D | 0.00 | 9,765,333 | 0 | 3,107,331 | 12.9 M to 3.1 M (-75.86 %) |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Sell | D | 0.00 | 1,160,148 | 0 | 290,409 | 1.5 M to 290.4 K (-79.98 %) |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 8.40 | 2,767,505 | 23,247,042 | 12,872,664 | 10.1 M to 12.9 M (+27.39 %) |
| Dec 20 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 8.40 | 250,037 | 2,100,311 | 1,450,557 | 1.2 M to 1.5 M (+20.83 %) |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | SIMPSON TODD E | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | SIMPSON TODD E | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | Noonberg Sarah B. | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | Noonberg Sarah B. | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | Nolan Sean P. | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | Nolan Sean P. | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | Williams Lewis T | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Oct 15 2019 | AQXP | Neoleukin Therapeu ... | Williams Lewis T | Director | Option Exercise | A | 2.82 | 22,000 | 62,040 | 22,000 | |
| Sep 11 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | See Remarks | Buy | P | 3.30 | 136,436 | 449,898 | 584,428 | 448 K to 584.4 K (+30.46 %) |
| Sep 11 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | See Remarks | Buy | P | 3.08 | 36,742 | 113,290 | 447,992 | 411.3 K to 448 K (+8.93 %) |
| Sep 11 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | See Remarks | Buy | P | 2.85 | 76,822 | 218,559 | 411,250 | 334.4 K to 411.3 K (+22.97 %) |
| Sep 04 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | See Remarks | Option Exercise | A | 2.80 | 1,650,000 | 4,620,000 | 1,650,000 | |
| Aug 12 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | President and CEO | Grant | A | 0.00 | 7,428 | 0 | 7,428 | 0 to 7.4 K |
| Aug 12 2019 | AQXP | Neoleukin Therapeu ... | DRACHMAN JONATHAN G | President and CEO | Grant | A | 0.00 | 334,428 | 0 | 334,428 | 0 to 334.4 K |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.15 | 50,436 | 159,020 | 10,105,159 | 10.1 M to 10.1 M (+0.50 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.15 | 4,564 | 14,390 | 1,200,520 | 1.2 M to 1.2 M (+0.38 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.02 | 209,382 | 633,255 | 10,054,723 | 9.8 M to 10.1 M (+2.13 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 3.02 | 18,943 | 57,291 | 1,195,956 | 1.2 M to 1.2 M (+1.61 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.96 | 5,869 | 17,358 | 9,845,341 | 9.8 M to 9.8 M (+0.06 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.96 | 531 | 1,570 | 1,177,013 | 1.2 M to 1.2 M (+0.05 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.85 | 65,568 | 186,666 | 9,839,472 | 9.8 M to 9.8 M (+0.67 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.85 | 5,932 | 16,888 | 1,176,482 | 1.2 M to 1.2 M (+0.51 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.83 | 9,445 | 26,756 | 9,773,904 | 9.8 M to 9.8 M (+0.10 %) |
| Aug 08 2019 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 2.83 | 855 | 2,422 | 1,170,550 | 1.2 M to 1.2 M (+0.07 %) |
| Aug 09 2018 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Option Exercise | A | 3.07 | 415,000 | 1,274,050 | 415,000 | |
| Aug 09 2018 | AQXP | AQUINOX PHARMACEUT ... | McCloskey Shelley | VP, HR and Administ ... | Option Exercise | A | 3.07 | 75,000 | 230,250 | 75,000 | |
| Aug 09 2018 | AQXP | AQUINOX PHARMACEUT ... | MacKenzie Lloyd | Chief Operating Off ... | Option Exercise | A | 3.07 | 145,000 | 445,150 | 145,000 | |
| Aug 09 2018 | AQXP | AQUINOX PHARMACEUT ... | Alam Kamran | CFO, Vice President ... | Option Exercise | A | 3.07 | 195,000 | 598,650 | 195,000 | |
| May 16 2018 | AQXP | AQUINOX PHARMACEUT ... | LEVITT DANIEL J | Director | Option Exercise | M | 10.56 | 3,906 | 41,247 | 0 | |
| May 16 2018 | AQXP | AQUINOX PHARMACEUT ... | LEVITT DANIEL J | Director | Sell | S | 12.67 | 3,906 | 49,489 | 0 | 3.9 K to 0 (-100.00 %) |
| May 16 2018 | AQXP | AQUINOX PHARMACEUT ... | LEVITT DANIEL J | Director | Buy | M | 10.56 | 3,906 | 41,247 | 3,906 | 0 to 3.9 K |
| May 09 2018 | AQXP | AQUINOX PHARMACEUT ... | SIMPSON TODD E | Director | Option Exercise | A | 13.10 | 15,000 | 196,500 | 15,000 | |
| May 09 2018 | AQXP | AQUINOX PHARMACEUT ... | Pelzer Robert | Director | Option Exercise | A | 13.10 | 15,000 | 196,500 | 15,000 | |
| May 09 2018 | AQXP | AQUINOX PHARMACEUT ... | Bridger Gary | Director | Option Exercise | A | 13.10 | 15,000 | 196,500 | 15,000 | |
| May 09 2018 | AQXP | AQUINOX PHARMACEUT ... | Nolan Sean P. | Director | Option Exercise | A | 13.10 | 15,000 | 196,500 | 15,000 | |
| May 09 2018 | AQXP | AQUINOX PHARMACEUT ... | LEVITT DANIEL J | Director | Option Exercise | A | 13.10 | 15,000 | 196,500 | 15,000 | |
| May 09 2018 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 13.10 | 30,000 | 393,000 | 30,000 | |
| Mar 19 2018 | AQXP | AQUINOX PHARMACEUT ... | MacKenzie Lloyd | Chief Operating Off ... | Option Exercise | M | 10.56 | 1,302 | 13,749 | 0 | |
| Mar 19 2018 | AQXP | AQUINOX PHARMACEUT ... | MacKenzie Lloyd | Chief Operating Off ... | Sell | S | 14.63 | 1,302 | 19,049 | 0 | 1.3 K to 0 (-100.00 %) |
| Mar 19 2018 | AQXP | AQUINOX PHARMACEUT ... | MacKenzie Lloyd | Chief Operating Off ... | Buy | M | 10.56 | 1,302 | 13,749 | 1,302 | 0 to 1.3 K |
| Mar 13 2018 | AQXP | AQUINOX PHARMACEUT ... | Troupin Barbara | Chief Medical Offic ... | Option Exercise | A | 16.55 | 75,000 | 1,241,250 | 75,000 | |
| Mar 13 2018 | AQXP | AQUINOX PHARMACEUT ... | McCloskey Shelley | VP, HR and Administ ... | Option Exercise | A | 16.55 | 45,000 | 744,750 | 45,000 | |
| Mar 13 2018 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Option Exercise | A | 16.55 | 225,000 | 3,723,750 | 225,000 | |
| Mar 13 2018 | AQXP | AQUINOX PHARMACEUT ... | MacKenzie Lloyd | Chief Operating Off ... | Option Exercise | A | 16.55 | 75,000 | 1,241,250 | 75,000 | |
| Mar 13 2018 | AQXP | AQUINOX PHARMACEUT ... | Jenkins Abigail | Chief Commercial Of ... | Option Exercise | A | 16.55 | 75,000 | 1,241,250 | 75,000 | |
| Mar 13 2018 | AQXP | AQUINOX PHARMACEUT ... | Alam Kamran | CFO, Vice President ... | Option Exercise | A | 16.55 | 75,000 | 1,241,250 | 75,000 | |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Option Exercise | M | 9.60 | 3,625 | 34,800 | 0 | |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Option Exercise | M | 9.60 | 6,000 | 57,600 | 3,625 | |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Option Exercise | M | 9.60 | 6,000 | 57,600 | 9,625 | |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Sell | S | 13.16 | 3,625 | 47,696 | 71,530 | 75.2 K to 71.5 K (-4.82 %) |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Buy | M | 9.60 | 3,625 | 34,800 | 75,155 | 71.5 K to 75.2 K (+5.07 %) |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Sell | S | 13.59 | 6,000 | 81,560 | 71,530 | 77.5 K to 71.5 K (-7.74 %) |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Buy | M | 9.60 | 6,000 | 57,600 | 77,530 | 71.5 K to 77.5 K (+8.39 %) |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Sell | S | 13.00 | 6,000 | 77,988 | 71,530 | 77.5 K to 71.5 K (-7.74 %) |
| Jun 05 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Buy | M | 9.60 | 6,000 | 57,600 | 77,530 | 71.5 K to 77.5 K (+8.39 %) |
| May 10 2017 | AQXP | AQUINOX PHARMACEUT ... | SIMPSON TODD E | Director | Option Exercise | A | 13.74 | 9,000 | 123,660 | 9,000 | |
| May 10 2017 | AQXP | AQUINOX PHARMACEUT ... | Nolan Sean P. | Director | Option Exercise | A | 13.74 | 9,000 | 123,660 | 9,000 | |
| May 10 2017 | AQXP | AQUINOX PHARMACEUT ... | Pelzer Robert | Director | Option Exercise | A | 13.74 | 9,000 | 123,660 | 9,000 | |
| May 10 2017 | AQXP | AQUINOX PHARMACEUT ... | LEVITT DANIEL J | Director | Option Exercise | A | 13.74 | 9,000 | 123,660 | 9,000 | |
| May 10 2017 | AQXP | AQUINOX PHARMACEUT ... | Bridger Gary | Director | Option Exercise | A | 13.74 | 9,000 | 123,660 | 9,000 | |
| May 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 13.74 | 36,000 | 494,640 | 36,000 | |
| Mar 10 2017 | AQXP | AQUINOX PHARMACEUT ... | Alam Kamran | CFO, Vice President ... | Option Exercise | A | 17.35 | 80,000 | 1,388,000 | 80,000 | |
| Mar 10 2017 | AQXP | AQUINOX PHARMACEUT ... | Troupin Barbara | Chief Medical Offic ... | Option Exercise | A | 17.35 | 40,000 | 694,000 | 40,000 | |
| Mar 10 2017 | AQXP | AQUINOX PHARMACEUT ... | Mitchell David Chilton | VP Global Regulator ... | Option Exercise | A | 17.35 | 25,000 | 433,750 | 25,000 | |
| Mar 10 2017 | AQXP | AQUINOX PHARMACEUT ... | McCloskey Shelley | VP, HR and Administ ... | Option Exercise | A | 17.35 | 30,000 | 520,500 | 30,000 | |
| Mar 10 2017 | AQXP | AQUINOX PHARMACEUT ... | Main David | President and CEO | Option Exercise | A | 17.35 | 185,000 | 3,209,750 | 185,000 | |
| Mar 10 2017 | AQXP | AQUINOX PHARMACEUT ... | MacKenzie Lloyd | VP Technical Operat ... | Option Exercise | A | 17.35 | 50,000 | 867,500 | 50,000 | |
| Mar 10 2017 | AQXP | AQUINOX PHARMACEUT ... | Jenkins Abigail | Chief Commercial Of ... | Option Exercise | A | 17.35 | 80,000 | 1,388,000 | 80,000 | |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 17.76 | 32,051 | 569,226 | 9,764,459 | 9.7 M to 9.8 M (+0.33 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 17.76 | 3,389 | 60,189 | 1,169,695 | 1.2 M to 1.2 M (+0.29 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 17.60 | 235,169 | 4,138,880 | 9,732,408 | 9.5 M to 9.7 M (+2.48 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 17.60 | 24,871 | 437,720 | 1,166,306 | 1.1 M to 1.2 M (+2.18 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.31 | 35,360 | 576,555 | 9,497,239 | 9.5 M to 9.5 M (+0.37 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.31 | 3,739 | 60,966 | 1,141,435 | 1.1 M to 1.1 M (+0.33 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.62 | 5,006 | 78,207 | 9,461,879 | 9.5 M to 9.5 M (+0.05 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.62 | 529 | 8,264 | 1,137,696 | 1.1 M to 1.1 M (+0.05 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.13 | 15,148 | 229,189 | 9,456,873 | 9.4 M to 9.5 M (+0.16 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.13 | 1,602 | 24,238 | 1,137,167 | 1.1 M to 1.1 M (+0.14 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.20 | 9,143 | 148,089 | 9,441,725 | 9.4 M to 9.4 M (+0.10 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 16.20 | 967 | 15,662 | 1,135,565 | 1.1 M to 1.1 M (+0.09 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.35 | 8,671 | 133,078 | 9,432,582 | 9.4 M to 9.4 M (+0.09 %) |
| Jan 09 2017 | AQXP | AQUINOX PHARMACEUT ... | BAKER BROS. ADVISORS LP | 10% Owner | Buy | P | 15.35 | 917 | 14,074 | 1,134,598 | 1.1 M to 1.1 M (+0.08 %) |